Summary
Signal counts
Assets tracked: 7
Watchlist assets: 7
Registry stop assets: 1
Sponsor overview
European Organisation for Research and Treatment of Cancer - EORTC
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00066378 | https://clinicaltrials.gov/study/NCT00057941 | https://clinicaltrials.gov/study/NCT01524926 | https://clinicaltrials.gov/study/NCT00003758 | https://clinicaltrials.gov/study/NCT01729845 | https://clinicaltrials.gov/study/NCT00064207 | https://clinicaltrials.gov/study/NCT00609336 | https://clinicaltrials.gov/study/NCT00004254 | https://clinicaltrials.gov/study/NCT00027781 | https://clinicaltrials.gov/study/NCT04402073
Assets
Linked programs
- anastrozole: Results Not Found Signal (3/5)
- Crizotinib (PF-02341066): Results Not Found Signal (3/5)
- cytarabine: Watchlist Signal (2/5)
- gemcitabine hydrochloride: Results Not Found Signal (2/5)
- raltitrexed: Results Not Found Signal (2/5)
- sabarubicin: Results Not Found Signal (2/5)
- Sonidegib: Registry Stop Signal (3/5)